Minhyuk Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Minhyuk Choi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Medellena Maria Glymour
Department of Epidemiology, Boston University School of Public Health, MA
3 shared publications - Akinyemi Oni-Orisan
Department of Clinical Pharmacy University of California San Francisco San Francisco California USA
2 shared publications - Catherine Schaefer
Kaiser Permanente Division of Research, Pleasanton, CA
2 shared publications - Chen Jiang
Kaiser Permanente, Division of Research
2 shared publications - Erin Laura Ferguson
University of California, San Francisco
2 shared publications - Kaitlin Swinnerton
Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System
2 shared publications
Latest Publications
- Open Access
- 22 July 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (2) , e213855
Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020
Previous research of associations between statins and Alzheimer disease and Alzheimer disease-related dementias (AD/ADRDs) has been limited by short follow-up, small samples, and confounding. We aimed to estimate the association between the 1st statin prescription and incident AD/ADRD among members of a large population-based cohort of older adults. We used a cohort study design emulating a target trial using data from Kaiser Permanente Northern California (KPNC), an integrated health care delivery system. Participants were born before 1951 and KPNC members for 4+ years during 1997-2010. Embedded subsamples included sociodemographic and genetic data. Statin initiators were matched at first prescription ("baseline") with up to 5 "noninitiators" based on age and low-density lipoprotein cholesterol (LDL-C). Participants with extreme propensity scores were excluded. The outcome was time to incident AD/ADRD diagnosis, censoring, or the administrative end of study (December 31, 2020). Cox proportional hazard models were used to estimate hazard ratios for statin initiation on AD/ADRD incidence. Follow-up time was divided at the first year of follow-up to account for increased AD/ADRD detection in the first year due to increased interaction with the health care system after a statin prescription. Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). The average follow-up was 11.8 years. In the first year after initiating statins, AD/ADRD diagnoses were elevated by 46% (hazard ratio [HR] = 1.46, 95% CI 1.42-1.53) compared with noninitiators. After 1 year, statin initiators experienced no difference in AD/ADRD incidence (full sample: HR = 1.00, 95% CI 0.99-1.01; subsample with survey covariates: HR = 1.01, 95% CI 0.98-1.06; subsample with survey and genetic covariates: HR = 0.97, 95% CI 0.91-1.07). Adjustment for sociodemographic covariates and apolipoprotein E e4 allele count did not materially change the findings. In this large emulated target trial, statin initiation was inconsistent with more than a 3% increase or decrease in the hazard of AD/ADRD after the first year of follow-up. This intent-to-treat analysis does not directly quantify effects of long-term exposure to statins. Associations in the first year likely reflect increased medical observation immediately after statin initiation. This emulated trial provides Class II evidence that statin initiation is not associated with AD/ADRD or AD incidence after the first year of follow-up.
- 22 July 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (2) , e213855
Open AccessStatin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020
Previous research of associations between statins and Alzheimer disease and Alzheimer disease-related dementias (AD/ADRDs) has been limited by short follow-up, small samples, and confounding. We aimed to estimate the association between the 1st statin prescription and incident AD/ADRD among members of a large population-based cohort of older adults. We used a cohort study design emulating a target trial using data from Kaiser Permanente Northern California (KPNC), an integrated health care delivery system. Participants were born before 1951 and KPNC members for 4+ years during 1997-2010. Embedded subsamples included sociodemographic and genetic data. Statin initiators were matched at first prescription ("baseline") with up to 5 "noninitiators" based on age and low-density lipoprotein cholesterol (LDL-C). Participants with extreme propensity scores were excluded. The outcome was time to incident AD/ADRD diagnosis, censoring, or the administrative end of study (December 31, 2020). Cox proportional hazard models were used to estimate hazard ratios for statin initiation on AD/ADRD incidence. Follow-up time was divided at the first year of follow-up to account for increased AD/ADRD detection in the first year due to increased interaction with the health care system after a statin prescription. Among eligible participants (n = 705,061), 264,294 individuals (37.5% of eligible participants) initiated any statin during 2001-2010 ("initiators"), of whom 249,613 (94.4%) were matched with 255,937 unique noninitiators to create the analytic sample (322,358 unique participants; mean age at baseline = 67.4 years; 55.1% female). The average follow-up was 11.8 years. In the first year after initiating statins, AD/ADRD diagnoses were elevated by 46% (hazard ratio [HR] = 1.46, 95% CI 1.42-1.53) compared with noninitiators. After 1 year, statin initiators experienced no difference in AD/ADRD incidence (full sample: HR = 1.00, 95% CI 0.99-1.01; subsample with survey covariates: HR = 1.01, 95% CI 0.98-1.06; subsample with survey and genetic covariates: HR = 0.97, 95% CI 0.91-1.07). Adjustment for sociodemographic covariates and apolipoprotein E e4 allele count did not materially change the findings. In this large emulated target trial, statin initiation was inconsistent with more than a 3% increase or decrease in the hazard of AD/ADRD after the first year of follow-up. This intent-to-treat analysis does not directly quantify effects of long-term exposure to statins. Associations in the first year likely reflect increased medical observation immediately after statin initiation. This emulated trial provides Class II evidence that statin initiation is not associated with AD/ADRD or AD incidence after the first year of follow-up.
- 27 February 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (4) , e208005
Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing
Rapid developments in Alzheimer disease (AD) biomarker research suggest that predictive testing may become widely available. To ensure equal access to AD predictive testing, it is important to understand factors that affect testing interest. Discrimination may influence attitudes toward AD testing, particularly among racially and ethnically minoritized populations, because of structural racism in health care systems. This study examined whether everyday or lifetime discrimination experiences shape interest in AD predictive testing. In the 2010 and 2012 biennial Health and Retirement Study waves, respondents were randomly selected to complete questions on interest in receiving free testing that could determine whether they would develop AD in the future. The exposures were everyday discrimination (6 items) and lifetime discrimination (7 items); both were transformed into a binary variable. Logistic regression models predicting interest in AD testing were controlled for deciles of propensity scores for each discrimination measure. Odds ratios were re-expressed as risk differences (RDs). Our analytic sample included 1,499 respondents. The mean age was 67 (SD = 10.2) years, 57.4% were women, 65.7% were White, and 80% endorsed interest in AD predictive testing. Most of the participants (54.7%) experienced everyday discrimination in at least one domain; 24.1% experienced major lifetime discrimination in at least one domain. Those interested in predictive testing were younger (66 vs 70 years) and more likely to be Black (20% vs 15%) or Latinx (14% vs 8%) than participants uninterested in testing. The probability of wanting an AD test was not associated with discrimination for Black (RD everyday discrimination = -0.026; 95% CI [-0.081 to 0.029]; RD lifetime discrimination = -0.012; 95% CI [-0.085 to 0.063]) or Latinx (RD everyday discrimination = -0.023, 95% CI [-0.082 to 0.039]; RD lifetime discrimination = -0.011; 95% CI [-0.087 to 0.064]) participants. Despite historical and contemporary experiences of discrimination, Black and Latinx individuals express interest in AD testing. However, Black and Latinx individuals remain underrepresented in AD research, including research on AD testing. Interest in personalized information about dementia risk may be a pathway to enhance their inclusion in research and clinical trials.
- 27 February 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (4) , e208005
Associations of Everyday and Lifetime Experiences of Discrimination With Willingness to Undergo Alzheimer Disease Predictive Testing
Rapid developments in Alzheimer disease (AD) biomarker research suggest that predictive testing may become widely available. To ensure equal access to AD predictive testing, it is important to understand factors that affect testing interest. Discrimination may influence attitudes toward AD testing, particularly among racially and ethnically minoritized populations, because of structural racism in health care systems. This study examined whether everyday or lifetime discrimination experiences shape interest in AD predictive testing. In the 2010 and 2012 biennial Health and Retirement Study waves, respondents were randomly selected to complete questions on interest in receiving free testing that could determine whether they would develop AD in the future. The exposures were everyday discrimination (6 items) and lifetime discrimination (7 items); both were transformed into a binary variable. Logistic regression models predicting interest in AD testing were controlled for deciles of propensity scores for each discrimination measure. Odds ratios were re-expressed as risk differences (RDs). Our analytic sample included 1,499 respondents. The mean age was 67 (SD = 10.2) years, 57.4% were women, 65.7% were White, and 80% endorsed interest in AD predictive testing. Most of the participants (54.7%) experienced everyday discrimination in at least one domain; 24.1% experienced major lifetime discrimination in at least one domain. Those interested in predictive testing were younger (66 vs 70 years) and more likely to be Black (20% vs 15%) or Latinx (14% vs 8%) than participants uninterested in testing. The probability of wanting an AD test was not associated with discrimination for Black (RD everyday discrimination = -0.026; 95% CI [-0.081 to 0.029]; RD lifetime discrimination = -0.012; 95% CI [-0.085 to 0.063]) or Latinx (RD everyday discrimination = -0.023, 95% CI [-0.082 to 0.039]; RD lifetime discrimination = -0.011; 95% CI [-0.087 to 0.064]) participants. Despite historical and contemporary experiences of discrimination, Black and Latinx individuals express interest in AD testing. However, Black and Latinx individuals remain underrepresented in AD research, including research on AD testing. Interest in personalized information about dementia risk may be a pathway to enhance their inclusion in research and clinical trials.
- 21 November 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (21) , E2172-E2184
Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan
Background and Objectives: The associations of high- and low-density lipoprotein cholesterol (HDL-C and LDL-C) with dementia risk in later life may be complex, and few studies have sufficient data to model non-linearities or adequately adjust for statin use. We evaluated the observational associations of HDL-C and LDL-C with incident dementia in a large and well-characterized cohort with linked survey and electronic health record (EHR) data. Methods: Kaiser Permanente Northern California health plan members aged 55 years and older who completed a health behavior survey between 2002 and 2007, had no history of dementia prior to the survey, and had laboratory measurements of cholesterol within two years after survey completion were followed through December 2020 for incident dementia (Alzheimer’s Disease Related Dementia [ADRD]; Alzheimer’s, vascular, and/or non-specific dementia) based on ICD9 or ICD10 codes in EHRs. We used Cox models for incident dementia with follow-up time beginning 2 years post-survey (after cholesterol measurement) and censoring at end of membership, death, or end of study period. We evaluated non-linearities using b-splines, adjusted for demographic, clinical, and survey confounders, and tested for effect modification by baseline age or prior statin use. Results: 184,367 participants [mean age at survey of 69.5 years, mean HDL-C=53.7 mg/dL (SD = 15.0), LDL-C=108 mg/dL (SD = 30.6)] were included. Higher and lower HDL-C values were associated with elevated ADRD risk compared to the middle quantile: HDL-C in the lowest quintile was associated with an HR of 1.07 (95% CI: 1.03-1.11) and HDL-C in the highest quintile was associated with an HR of 1.15 (95% CI: 1.11-1.20). LDL-C was not associated with dementia risk overall, but statin use qualitatively modified the association. Higher LDL-C was associated with slightly greater risk of ADRD for statin users (53% of the sample, HR per 10 mg/dL increase=1.01, 95% CI: 1.01-1.02) and lower risk for non-users (HR per 10 mg/dL increase=0.98; 95% CI: 0.97-0.99). There was evidence for effect modification by age with linear HDL-C (p=0.003) but not LDL-C (p=0.59). Discussion: Both low and high levels of HDL-C were associated with elevated dementia risk. The association between LDL-C and dementia risk was modest.
- 21 November 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 101 (21) , E2172-E2184
Low- and High-Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members of a Large Health Care Plan
Background and Objectives: The associations of high- and low-density lipoprotein cholesterol (HDL-C and LDL-C) with dementia risk in later life may be complex, and few studies have sufficient data to model non-linearities or adequately adjust for statin use. We evaluated the observational associations of HDL-C and LDL-C with incident dementia in a large and well-characterized cohort with linked survey and electronic health record (EHR) data. Methods: Kaiser Permanente Northern California health plan members aged 55 years and older who completed a health behavior survey between 2002 and 2007, had no history of dementia prior to the survey, and had laboratory measurements of cholesterol within two years after survey completion were followed through December 2020 for incident dementia (Alzheimer’s Disease Related Dementia [ADRD]; Alzheimer’s, vascular, and/or non-specific dementia) based on ICD9 or ICD10 codes in EHRs. We used Cox models for incident dementia with follow-up time beginning 2 years post-survey (after cholesterol measurement) and censoring at end of membership, death, or end of study period. We evaluated non-linearities using b-splines, adjusted for demographic, clinical, and survey confounders, and tested for effect modification by baseline age or prior statin use. Results: 184,367 participants [mean age at survey of 69.5 years, mean HDL-C=53.7 mg/dL (SD = 15.0), LDL-C=108 mg/dL (SD = 30.6)] were included. Higher and lower HDL-C values were associated with elevated ADRD risk compared to the middle quantile: HDL-C in the lowest quintile was associated with an HR of 1.07 (95% CI: 1.03-1.11) and HDL-C in the highest quintile was associated with an HR of 1.15 (95% CI: 1.11-1.20). LDL-C was not associated with dementia risk overall, but statin use qualitatively modified the association. Higher LDL-C was associated with slightly greater risk of ADRD for statin users (53% of the sample, HR per 10 mg/dL increase=1.01, 95% CI: 1.01-1.02) and lower risk for non-users (HR per 10 mg/dL increase=0.98; 95% CI: 0.97-0.99). There was evidence for effect modification by age with linear HDL-C (p=0.003) but not LDL-C (p=0.59). Discussion: Both low and high levels of HDL-C were associated with elevated dementia risk. The association between LDL-C and dementia risk was modest.